These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34023149)

  • 81. Authors' response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Chang JW; Kim SU
    J Viral Hepat; 2021 Mar; 28(3):574. PubMed ID: 33305419
    [No Abstract]   [Full Text] [Related]  

  • 82. Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction".
    Kim BK
    J Hepatol; 2019 Oct; 71(4):847-848. PubMed ID: 31383378
    [No Abstract]   [Full Text] [Related]  

  • 83. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
    J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
    Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
    Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Interdisciplinary aspects of and new drugs for chronic hepatitis B].
    Horváth G
    Orv Hetil; 2013 Jul; 154(29):1142-50. PubMed ID: 23853347
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
    Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
    Batirel A; Guclu E; Arslan F; Kocak F; Karabay O; Ozer S; Turanli M; Mert A
    Int J Infect Dis; 2014 Nov; 28():153-9. PubMed ID: 25286184
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
    Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
    Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
    Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Managing hepatitis B to prevent liver cancer: recent advances.
    Strasser SI
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):409-15. PubMed ID: 24580046
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy.
    Chan HLY
    J Gastroenterol Hepatol; 2019 Mar; 34(3):501-506. PubMed ID: 30402981
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B.
    Ibragimov EK; Abdurakhmanov DT; Rozina TP; Nikulkina EN; Tanaschuk EL; Odintsov AV; Panevkina SV; Moiseev SV
    Ter Arkh; 2019 Mar; 91(2):40-47. PubMed ID: 31094170
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
    Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B.
    Yegin EG; Ozdogan OC
    Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):602-11. PubMed ID: 25475862
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Doğan ÜB; Kara B; Gümürdülü Y; Soylu A; Akin MS
    Turk J Gastroenterol; 2012 Jun; 23(3):247-52. PubMed ID: 22798114
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 97. New approaches in viraemic organ transplantation and antiviral therapies.
    Holmes JA; Chung RT
    Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):78-79. PubMed ID: 31915372
    [No Abstract]   [Full Text] [Related]  

  • 98. [Evaluation of Histological Response in Chronic Hepatitis B Patients with Tenofovir or Entecavir Therapy].
    Çerçioğlu D; Kınıklı S; Cesur S; Ataman Hatipoğlu Ç; Arslan K; Gönültaş M
    Mikrobiyol Bul; 2020 Jan; 54(1):95-109. PubMed ID: 32050881
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
    Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
    Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
    [TBL] [Abstract][Full Text] [Related]  

  • 100. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.